Research and development are on soar for testing the efficiency of drug for the treatment of liver disease and this is driving the hepatic encephalopathy market. Another factor playing in growth is increasing submissions of abbreviated new drug application. Pandemic Covid-19 played negatively by hindering the supply of drugs, growth and production. Also, high cost of rifaximin used for the treatment of hepatic encephalopathy also is the restraining factor for the growth of market.
According to Coherent market insights, the global Hepatic Encephalopathy Market is estimated to be valued at US$ 355.4 Mn in 2020 and is expected to exhibit a CAGR of 5.3% over the forecast period (2020-2027).
Key Leaders in the Hepatic Encephalopathy Industry:
1. ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company was founded in 1920 and is headquartered in Tokyo, Japan
2. Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide.In January 2021, Cosmo announced the successful outcome of our Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX® 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D) showing a statistically significant improvement of the disease over placebo at the daily dose of 1,200 mg.
3. Lupin Limited
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. t operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil.
4. Kaleido Biosciences
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.it was incorporated in 2015 and is headquartered in Lexington, Massachusetts. On Dec. 12, 2019, kaleido biosciences announced positive top-line results from a proof-of-concept clinical study of KB174 using a 15N-labeled tracer in patients with well-compensated cirrhosis.
5. Kannalife Sciences, Inc.
Kannalife, a subsidiary of Neuropathix, Inc. (OTCQB: NPTX), is a biopharmaceutical company focused on the research and development of a pipeline of next generation cannabinoid-inspired therapeutics as potent, non-opioid alternatives to treat patients with significant unmet medical needs. the only company in the cannabinoid therapeutics arena to have licensed the U.S. Government Patent 6,630,507 – “Cannabinoids as Antioxidants and Neuroprotectants”. The company was founded on 2010, headquartered in Pennsylvania, U.S.
6. Bausch Health Companies Inc
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It was founded in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. On Aug. 10, 2022 Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.
7. Mallinckrodt Pharmaceuticals
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company was founded in 1867 and is based in Dublin, Ireland.
8. Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
9. Umecrine Cognition AB
On March 17, 2017. Karolinska Development's portfolio company Umecrine Cognition AB announced the inclusion of the first patient in a clinical Phase Ib/IIa study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy. The company was founded in 2006, headquartered in Sweden.
10. Ferring Pharmaceuticals Inc
Headquartered in Switzerland. The founded in 1980. Ferring is research-driven, especially biopharmaceutical group committed to helping people build healthy families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas withing gastroenterology and urology.
*Definition- hepatic encephalopathy is associated with acute liver failure, liver cirrhosis and end stage liver diseases that lead to mortality.
